Paul DawidczykVP, Regulatory Affairs CMC at Moderna Therapeutics
Mr. Dawidczyk joined Moderna in May 2017 and is currently the Vice President of Regulatory Affairs CMC for Moderna’s rare disease, infectious disease, oncology and cardiovascular programs. Mr. Dawidczyk has over 30 years of pharmaceutical and biotechnology experience with proteins, messenger RNA, monoclonal antibodies, small molecules, cellular therapies, oligonucleotides, IVDs, combination products (biologics/device) and medical devices. Prior to joining Moderna, Mr. Dawidczyk was the Director of Regulatory Affairs CMC supporting the enzyme replacement therapy programs at Sanofi Genzyme. Mr. Dawidczyk received a BS in Biochemistry from the University of Massachusetts at Amherst.